A New Topical Candidate in Acne Treatment: Characterization of the Meclozine Hydrochloride as an Anti-Inflammatory Compound from In Vitro to a Preliminary Clinical Study.

Autor:	Grange PA; Département DRC, Développement, Reproduction et Cancer, Institut Cochin, INSERM U1016-CNRS UMR8104, Université de Paris Cité, 75014 Paris, France.; Service de Dermatologie-Vénéréologie et CeGIDD, Groupe Hospitalier APHP.5, CNR IST Bactériennes-Laboratoire Associé Syphilis, 75014 Paris, France.; SkinDermic, 75014 Paris, France., Ollagnier G; Département DRC, Développement, Reproduction et Cancer, Institut Cochin, INSERM U1016-CNRS UMR8104, Université de Paris Cité, 75014 Paris, France.; Service de Dermatologie-Vénéréologie et CeGIDD, Groupe Hospitalier APHP.5, CNR IST Bactériennes-Laboratoire Associé Syphilis, 75014 Paris, France., Beauvais Remigereau L; SkinDermic, 75014 Paris, France., Nicco C; Département 3I, Infection, Immunité et Inflammation, Institut Cochin, INSERM U1016-CNRS UMR8104, Université de Paris Cité, 75014 Paris, France., Mayslich C; Département DRC, Développement, Reproduction et Cancer, Institut Cochin, INSERM U1016-CNRS UMR8104, Université de Paris Cité, 75014 Paris, France., Marcelin AG; SkinDermic, 75014 Paris, France.; Service de Virologie, Hôpital Pitié Salpêtrière, APHP, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), INSERM UMR_1136, Sorbonne Université, Virologie, 75013 Paris, France., Calvez V; SkinDermic, 75014 Paris, France.; Service de Virologie, Hôpital Pitié Salpêtrière, APHP, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), INSERM UMR_1136, Sorbonne Université, Virologie, 75013 Paris, France., Dupin N; Département DRC, Développement, Reproduction et Cancer, Institut Cochin, INSERM U1016-CNRS UMR8104, Université de Paris Cité, 75014 Paris, France.; Service de Dermatologie-Vénéréologie et CeGIDD, Groupe Hospitalier APHP.5, CNR IST Bactériennes-Laboratoire Associé Syphilis, 75014 Paris, France.; SkinDermic, 75014 Paris, France.
Jazyk:	angličtina
Zdroj:	Biomedicines [Biomedicines] 2022 Apr 19; Vol. 10 (5). Date of Electronic Publication: 2022 Apr 19.
DOI:	10.3390/biomedicines10050931
Abstrakt:	Acne is a chronic inflammatory multifactorial disease involving the anaerobic bacterium Cutibacterium acnes (C. acnes). Current acne treatments are associated with adverse effects, limiting treatment compliance and use. We showed that meclozine, an anti-histaminic H1 compound, has anti-inflammatory properties. In Vitro, meclozine reduced the production of CXCL8/IL-8 and IL-1β mRNA and protein by C. acnes-stimulated human keratinocytes and monocytes. No cell toxicity was observed at the IC50. Meclozine prevented the phosphorylation of ERK and JNK. In Vivo, 1% meclozine gel significantly decreased C. acnes-mouse ear induced inflammation by 26.7% (p = 0.021). Ex vivo experiments on human skin explants showed that meclozine decreased the production of GM-CSF, IL-1β and TNF-α at transcriptional and translational levels. In a randomized, double-blind, placebo-controlled proof-of-concept clinical trial on 60 volunteers, 2% meclozine pharmaceutical gel decreased by 20.1% (p < 0.001) the ASI score in the treated group after 12 weeks of treatment. No adverse event was reported. Together, these results indicate that meclozine is a potent topical anti-inflammatory compound of potential value for acne treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu